Quest PharmaTech Inc. (QPT.V)

0.0900 -0.0050 (-5.26%) At close: 03:50PM EDT

Quest PharmaTech Inc.

8123 Roper Road NW
Edmonton, AB T6E 6S4
Canada
780 448 1400
https://www.questpharmatech.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Ragupathy Madiyalakan	CEO & Director	40k	N/A	N/A
Mr. Pierre Vermette	Chief Financial Officer	70k	N/A	N/A
Mr. Roger Andrews	Head of Investor Relations & Corp. Communications	N/A	N/A	N/A
Mr. Douglas C. Bachman	VP of Corp. Devel.	N/A	N/A	1954
Mr. Thomas Woo	VP of Product Devel.	N/A	N/A	N/A

Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.

Description

Quest PharmaTech Inc., a biopharmaceutical company, develops and commercializes antibody based immunotherapeutic products for cancer. Its lead product candidates are Mab AR 9.6 against truncated O-glycan on MUC16 for targeted cancer therapy applications; and Oregovomab, an anti-CA-125 antibody, which has completed Phase II clinical trial for the treatment of ovarian cancer. The company also develops combinatorial immunotherapeutic products for cancer by using monoclonal antibodies of the immunoglobulin G and E class in combination with chemotherapy/immune-adjuvant; and immunotherapy products for pancreatic cancer. In addition, it develops products by using proprietary transdermal delivery technologies for dermatology and wound healing applications; and skin penetrating active molecules for cosmetic and pharmaceutical use. Quest PharmaTech Inc. is headquartered in Edmonton, Canada.

Corporate Governance

Quest PharmaTech Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.